ONCY Stock Forecast & Price Target

Oncolytics Biotech is supported by a sharpened GI-focused strategy that concentrates capital on pelareorep’s most promising and FDA-aligned programs, especially the randomized REO 033 study in 2L RAS-mutated MSS mCRC and the de-risked SCAC path. The FDA’s written feedback on REO 033 and Fast Track designation in SCAC strengthen the regulatory case for a capital-efficient registrational design that could support accelerated and full approval within one study, while translational data showing 33% ORR, 19.5-month duration of response, 16.6-month PFS, and 27-month OS versus historical benchmarks reinforce the drug’s clinical differentiation. Although cash and cash equivalents were only $4.1 million as of June 30 and a Nasdaq minimum bid price notice creates a January 2027 decision point, the company’s ATM access, partnership optionality, and 2044 patent protection for key manufacturing IP help preserve long-term upside.

Oncolytics Biotech is facing a deteriorating fundamental profile because the SCAC and mPDAC programs are now effectively partner-dependent, with the pivotal SCAC protocol still being finalized and the prior late-3Q26 start slipping into an open-ended timeline. Its balance sheet remains fragile, with just $4.1 million in cash as of June 30 and only $6.8 million raised net from ATM sales, which was not enough to fund planned operations for at least twelve months without continued capital raises. The weak funding position, lower SCAC probability of success, and delayed GOBLET catalyst sharply reduce visibility on future value creation while increasing dilution risk and pressure on the stock.